Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Distribution and molecular characterization of beta-lactamases in Gram-negative bacteria in Colombia, 2001-2016

Rada AM, Hernández-Gómez C, Restrepo E, Villegas MV.

Biomedica. 2019 May 1;39(s1):199-220. doi: 10.7705/biomedica.v39i3.4351. English, Spanish.

2.

Clostridium difficile infection: Description of NAP1/027 and non NAP1/027 strains in a high complexity center in Cali, Colombia, 2012-2015

Oñate-Gutiérrez JM, Segura J, Correa A, Cantor E, Villegas MV.

Biomedica. 2019 May 1;39(s1):63-70. doi: 10.7705/biomedica.v39i2.3950. English, Spanish.

3.

Clinical and economic impact of generic versus brand name meropenem use in an intensive care unit in Colombia.

Ordóñez K, Feinstein MM, Reyes S, Hernández-Gómez C, Pallares C, Villegas MV.

Braz J Infect Dis. 2019 Jul - Aug;23(4):237-245. doi: 10.1016/j.bjid.2019.06.010. Epub 2019 Jul 22.

4.

[Clinical impact of ertapenem de-escalation in critically-ill patients with Enterobacteriaceae infections].

Cuesta DP, Blanco VM, Vallejo ME, Hernández-Gómez C, Maya JJ, Motoa G, Correa A, Matta L, Rosso F, Camargo RD, Muñoz M, Florez E, Nagles J, Ovalle A, Reyes S, Villegas MV.

Rev Chilena Infectol. 2019 Feb;36(1):9-15. doi: 10.4067/S0716-10182019000100009. Spanish.

5.

Detection of carbapenemase-producing Pseudomonas aeruginosa: Evaluation of the carbapenem inactivation method (CIM).

Gutiérrez S, Correa A, Hernández-Gómez C, De La Cadena E, Pallares C, Villegas MV.

Enferm Infecc Microbiol Clin. 2019 Mar 18. pii: S0213-005X(19)30127-2. doi: 10.1016/j.eimc.2019.02.004. [Epub ahead of print] English, Spanish.

PMID:
30898368
6.

Gram-negative infections: evolving treatments with expanding options.

Villegas MV, Lyon S.

Future Sci OA. 2018 Sep 27;4(9):FSO339. doi: 10.4155/fsoa-2018-0071. eCollection 2018 Oct.

7.

Molecular characterisation of carbapenem-resistant Enterobacter cloacae complex in Colombia: blaKPC and the 'changing landscape'.

De La Cadena E, Correa A, Muñoz JS, Rojas LJ, Hernández-Gómez C, Pallares C, Perez F, Bonomo RA, Villegas MV.

J Glob Antimicrob Resist. 2018 Jun;13:184-189. doi: 10.1016/j.jgar.2017.12.008. Epub 2017 Dec 20.

PMID:
29274468
8.

An Analysis of the Epidemic of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Convergence of Two Evolutionary Mechanisms Creates the "Perfect Storm".

Rojas LJ, Weinstock GM, De La Cadena E, Diaz L, Rios R, Hanson BM, Brown JS, Vats P, Phillips DS, Nguyen H, Hujer KM, Correa A, Adams MD, Perez F, Sodergren E, Narechania A, Planet PJ, Villegas MV, Bonomo RA, Arias CA.

J Infect Dis. 2017 Dec 27;217(1):82-92. doi: 10.1093/infdis/jix524.

9.

Genomic and Molecular Characterization of Clinical Isolates of Enterobacteriaceae Harboring mcr-1 in Colombia, 2002 to 2016.

Saavedra SY, Diaz L, Wiesner M, Correa A, Arévalo SA, Reyes J, Hidalgo AM, de la Cadena E, Perenguez M, Montaño LA, Ardila J, Ríos R, Ovalle MV, Díaz P, Porras P, Villegas MV, Arias CA, Beltrán M, Duarte C.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00841-17. doi: 10.1128/AAC.00841-17. Print 2017 Dec.

10.

High-Level Resistance to Colistin Mediated by Various Mutations in the crrB Gene among Carbapenemase-Producing Klebsiella pneumoniae.

Jayol A, Nordmann P, Brink A, Villegas MV, Dubois V, Poirel L.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01423-17. doi: 10.1128/AAC.01423-17. Print 2017 Nov.

11.

Antibiotic stewardship in low- and middle-income countries: the same but different?

Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV, Gould I, Levy Hara G.

Clin Microbiol Infect. 2017 Nov;23(11):812-818. doi: 10.1016/j.cmi.2017.07.010. Epub 2017 Jul 14. Review.

12.

Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.

Tamma PD, Villegas MV.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e01094-17. doi: 10.1128/AAC.01094-17. Print 2017 Aug.

13.

Distinct Genetic Diversity of Carbapenem-Resistant Acinetobacter baumannii from Colombian Hospitals.

Correa A, Del Campo R, Escandón-Vargas K, Perenguez M, Rodríguez-Baños M, Hernández-Gómez C, Pallares C, Perez F, Arias CA, Cantón R, Villegas MV.

Microb Drug Resist. 2018 Jan/Feb;24(1):48-54. doi: 10.1089/mdr.2016.0190. Epub 2017 Jun 1.

14.

A Comparison of Molecular Typing Methods Applied to Enterobacter cloacae complex: hsp60 Sequencing, Rep-PCR, and MLST.

Viau RA, Kiedrowski LM, Kreiswirth BN, Adams M, Perez F, Marchaim D, Guerrero DM, Kaye KS, Logan LK, Villegas MV, Bonomo RA.

Pathog Immun. 2017;2(1):23-33. doi: 10.20411/pai.v2i1.99. Epub 2017 Feb 1.

15.

Improved Outcomes When Antibiotic Prescribing Guidelines Are Followed by Healthcare Providers: A Colombian Example to Encourage Adherence in Hospital Settings.

Feinstein MM, Escandón-Vargas K, Reyes S, Hernández-Gómez C, Pallares CJ, Villegas MV.

Infect Control Hosp Epidemiol. 2017 Jun;38(6):756-758. doi: 10.1017/ice.2017.45. Epub 2017 Apr 3. No abstract available. Erratum in: Infect Control Hosp Epidemiol. 2018 Jul;39(7):893.

PMID:
28366177
16.

The epidemiology of carbapenemases in Latin America and the Caribbean.

Escandón-Vargas K, Reyes S, Gutiérrez S, Villegas MV.

Expert Rev Anti Infect Ther. 2017 Mar;15(3):277-297. doi: 10.1080/14787210.2017.1268918. Epub 2016 Dec 20. Review.

PMID:
27915487
17.

A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail.

Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, Cairns KA, Escandón-Vargas K, Villegas MV, Brink A, van den Bergh D, Mendelson M.

Lancet Infect Dis. 2017 Feb;17(2):e56-e63. doi: 10.1016/S1473-3099(16)30386-3. Epub 2016 Nov 18. Review.

PMID:
27866945
18.

Epidemiology of Candida isolates from Intensive Care Units in Colombia from 2010 to 2013.

Motoa G, Muñoz JS, Oñate J, Pallares CJ, Hernández C, Villegas MV.

Rev Iberoam Micol. 2017 Jan - Mar;34(1):17-22. doi: 10.1016/j.riam.2016.02.006. Epub 2016 Oct 31.

PMID:
27810262
19.

[Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].

Blanco VM, Maya JJ, Correa A, Perenguez M, Muñoz JS, Motoa G, Pallares CJ, Rosso F, Matta L, Celis Y, Garzon M, Villegas MV.

Enferm Infecc Microbiol Clin. 2016 Nov;34(9):559-565. doi: 10.1016/j.eimc.2015.11.017. Epub 2016 Jan 13. Spanish.

20.

[Clinical and microbiological characteristics of complicated intra-abdominal infection in Colombia: a multicenter study].

Vallejo M, Cuesta DP, Flórez LE, Correa A, Llanos CE, Isaza B, Vanegas S, Osorio J, Casanova L, Villegas MV.

Rev Chilena Infectol. 2016 Jun;33(3):261-7. doi: 10.4067/S0716-10182016000300002. Spanish.

21.

Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.

Villegas MV, Pallares CJ, Escandón-Vargas K, Hernández-Gómez C, Correa A, Álvarez C, Rosso F, Matta L, Luna C, Zurita J, Mejía-Villatoro C, Rodríguez-Noriega E, Seas C, Cortesía M, Guzmán-Suárez A, Guzmán-Blanco M.

PLoS One. 2016 Apr 22;11(4):e0154092. doi: 10.1371/journal.pone.0154092. eCollection 2016.

22.

Initial Assessment of the Molecular Epidemiology of blaNDM-1 in Colombia.

Rojas LJ, Wright MS, De La Cadena E, Motoa G, Hujer KM, Villegas MV, Adams MD, Bonomo RA.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4346-50. doi: 10.1128/AAC.03072-15. Print 2016 Jul.

23.

Introduction of software tools for epidemiological surveillance in infection control in Colombia.

Hernández-Gómez C, Motoa G, Vallejo M, Blanco VM, Correa A, de la Cadena E, Villegas MV.

Colomb Med (Cali). 2015 Jun 30;46(2):60-5. eCollection 2015 Apr-Jun.

24.

The role of surveillance systems in confronting the global crisis of antibiotic-resistant bacteria.

Perez F, Villegas MV.

Curr Opin Infect Dis. 2015 Aug;28(4):375-83. doi: 10.1097/QCO.0000000000000182. Review.

25.

Modulation of mgrB gene expression as a source of colistin resistance in Klebsiella oxytoca.

Jayol A, Poirel L, Villegas MV, Nordmann P.

Int J Antimicrob Agents. 2015 Jul;46(1):108-10. doi: 10.1016/j.ijantimicag.2015.02.015. Epub 2015 Mar 28.

PMID:
25982250
26.

Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-β-lactamases.

Mojica MF, Mahler SG, Bethel CR, Taracila MA, Kosmopoulou M, Papp-Wallace KM, Llarrull LI, Wilson BM, Marshall SH, Wallace CJ, Villegas MV, Harris ME, Vila AJ, Spencer J, Bonomo RA.

Biochemistry. 2015 May 26;54(20):3183-96. doi: 10.1021/acs.biochem.5b00106. Epub 2015 May 12.

27.

Dissemination of high-risk clones of extensively drug-resistant Pseudomonas aeruginosa in colombia.

Correa A, Del Campo R, Perenguez M, Blanco VM, Rodríguez-Baños M, Perez F, Maya JJ, Rojas L, Cantón R, Arias CA, Villegas MV.

Antimicrob Agents Chemother. 2015 Apr;59(4):2421-5. doi: 10.1128/AAC.03926-14. Epub 2015 Jan 20.

28.

The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae.

Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Türkoglu S, Nordmann P.

J Antimicrob Chemother. 2015 Jan;70(1):75-80. doi: 10.1093/jac/dku323. Epub 2014 Sep 3.

PMID:
25190723
29.

[Evolution of antimicrobial resistance in Gram negative bacilli from intensive care units in Colombia].

Hernández-Gómez C, Blanco VM, Motoa G, Correa A, Vallejo M, Villegas MV; Grupo de Resistencia Bacteriana Nosocomial en Colombia.

Biomedica. 2014 Apr;34 Suppl 1:91-100. doi: 10.1590/S0120-41572014000500011. Spanish.

PMID:
24968040
30.

[Prevalence of Gram-negative bacteria harboring bla KPC gene in Colombian hospitals].

Pacheco R, Osorio L, Correa AM, Villegas MV.

Biomedica. 2014 Apr;34 Suppl 1:81-90. doi: 10.1590/S0120-41572014000500010. Spanish.

PMID:
24968039
31.

Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin.

Jayol A, Poirel L, Brink A, Villegas MV, Yilmaz M, Nordmann P.

Antimicrob Agents Chemother. 2014 Aug;58(8):4762-6. doi: 10.1128/AAC.00084-14. Epub 2014 Jun 9.

32.

Extended spectrum β-lactamase producers among nosocomial Enterobacteriaceae in Latin America.

Guzmán-Blanco M, Labarca JA, Villegas MV, Gotuzzo E; Latin America Working Group on Bacterial Resistance.

Braz J Infect Dis. 2014 Jul-Aug;18(4):421-33. doi: 10.1016/j.bjid.2013.10.005. Epub 2014 Jan 3. Review.

33.

Emergence of OXA-72-producing Acinetobacter pittii clinical isolates.

Bonnin RA, Docobo-Pérez F, Poirel L, Villegas MV, Nordmann P.

Int J Antimicrob Agents. 2014 Feb;43(2):195-6. doi: 10.1016/j.ijantimicag.2013.10.005. Epub 2013 Nov 5. No abstract available.

PMID:
24355573
34.

Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing Klebsiella pneumoniae clone.

Adler A, Khabra E, Chmelnitsky I, Giakkoupi P, Vatopoulos A, Mathers AJ, Yeh AJ, Sifri CD, De Angelis G, Tacconelli E, Villegas MV, Quinn J, Carmeli Y.

Diagn Microbiol Infect Dis. 2014 Jan;78(1):12-5. doi: 10.1016/j.diagmicrobio.2013.10.003. Epub 2013 Oct 14.

PMID:
24231383
35.

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP.

Lancet Infect Dis. 2013 Sep;13(9):785-96. doi: 10.1016/S1473-3099(13)70190-7. Review.

36.

Resistant gram-negative infections in the outpatient setting in Latin America.

Salles MJ, Zurita J, Mejía C, Villegas MV; Latin America Working Group on Bacterial Resistance.

Epidemiol Infect. 2013 Dec;141(12):2459-72. doi: 10.1017/S095026881300191X. Epub 2013 Aug 7. Review.

37.

Current status of carbapenemases in Latin America.

Maya JJ, Ruiz SJ, Blanco VM, Gotuzzo E, Guzman-Blanco M, Labarca J, Salles M, Quinn JP, Villegas MV.

Expert Rev Anti Infect Ther. 2013 Jul;11(7):657-67. doi: 10.1586/14787210.2013.811924.

PMID:
23879607
38.

Dissemination of the KPC-2 carbapenemase in non-Klebsiella pneumoniae enterobacterial isolates from Colombia.

Cuzon G, Naas T, Correa A, Quinn JP, Villegas MV, Nordmann P.

Int J Antimicrob Agents. 2013 Jul;42(1):59-62. doi: 10.1016/j.ijantimicag.2013.04.002. Epub 2013 May 9.

PMID:
23664581
39.

First report of a nonmetallocarbapenemase class A carbapenemase in an Enterobacter cloacae isolate from Colombia.

Blanco VM, Rojas LJ, De La Cadena E, Maya JJ, Camargo RD, Correa A, Quinn JP, Villegas MV.

Antimicrob Agents Chemother. 2013 Jul;57(7):3457. doi: 10.1128/AAC.02425-12. Epub 2013 Apr 22. No abstract available.

40.

Complete sequence of two KPC-harbouring plasmids from Pseudomonas aeruginosa.

Naas T, Bonnin RA, Cuzon G, Villegas MV, Nordmann P.

J Antimicrob Chemother. 2013 Aug;68(8):1757-62. doi: 10.1093/jac/dkt094. Epub 2013 Apr 7.

PMID:
23569197
41.

Emergence of Klebsiella pneumoniae Coharboring KPC and VIM Carbapenemases in Colombia.

Rojas LJ, Mojica MF, Blanco VM, Correa A, Montealegre MC, De La Cadena E, Maya JJ, Camargo RD, Quinn JP, Villegas MV.

Antimicrob Agents Chemother. 2013 Feb;57(2):1101-2. doi: 10.1128/AAC.01666-12. Epub 2012 Dec 10. No abstract available.

42.

First report of a Pseudomonas aeruginosa isolate coharboring KPC and VIM carbapenemases.

Correa A, Montealegre MC, Mojica MF, Maya JJ, Rojas LJ, De La Cadena EP, Ruiz SJ, Recalde M, Rosso F, Quinn JP, Villegas MV.

Antimicrob Agents Chemother. 2012 Oct;56(10):5422-3. doi: 10.1128/AAC.00695-12. Epub 2012 Jul 23. No abstract available.

43.

Molecular correlates of the spread of KPC-producing Enterobacteriaceae in Colombia.

Mojica MF, Correa A, Vargas DA, Maya JJ, Montealegre MC, Rojas LJ, Ruiz SJ, Quinn JP, Villegas MV; Colombian Nosocomial Bacterial Resistance Study Group.

Int J Antimicrob Agents. 2012 Sep;40(3):277-9. Epub 2012 Jul 11. No abstract available.

PMID:
22789725
44.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hackel MA, Lascols CA, Villegas MV, Rossi F.

J Chemother. 2012 Feb;24(1):6-11. doi: 10.1179/1120009X12Z.0000000003.

PMID:
22546718
45.

First identification of OXA-72 carbapenemase from Acinetobacter pittii in Colombia.

Montealegre MC, Maya JJ, Correa A, Espinal P, Mojica MF, Ruiz SJ, Rosso F, Vila J, Quinn JP, Villegas MV.

Antimicrob Agents Chemother. 2012 Jul;56(7):3996-8. doi: 10.1128/AAC.05628-11. Epub 2012 Apr 16.

46.

Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.

Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.

Braz J Infect Dis. 2011 Sep-Oct;15(5):413-9.

47.

Wide dissemination of Pseudomonas aeruginosa producing beta-lactamase blaKPC-2 gene in Colombia.

Cuzon G, Naas T, Villegas MV, Correa A, Quinn JP, Nordmann P.

Antimicrob Agents Chemother. 2011 Nov;55(11):5350-3. doi: 10.1128/AAC.00297-11. Epub 2011 Aug 15.

48.

[Antimicrobial resistance of Gram negative bacilli isolated from tertiary-care hospitals in Colombia].

Briceño DF, Correa A, Valencia C, Torres JA, Pacheco R, Montealegre MC, Ospina D, Villegas MV; Grupo de Resistencia Bacteriana Nosocomial de Colombia.

Biomedica. 2010 Jul-Sep;30(3):371-81. Spanish.

PMID:
21713339
50.

First characterization of CTX-M-15-producing Escherichia coli ST131 and ST405 clones causing community-onset infections in South America.

Ruiz SJ, Montealegre MC, Ruiz-Garbajosa P, Correa A, Briceño DF, Martinez E, Rosso F, Muñoz M, Quinn JP, Cantón R, Villegas MV.

J Clin Microbiol. 2011 May;49(5):1993-6. doi: 10.1128/JCM.00045-11. Epub 2011 Feb 16.

Supplemental Content

Loading ...
Support Center